Patent · US Active

Herpes simplex virus vaccine

US11752206B2 · kind B2 · utility

17Cited by

60References

9Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Giuseppe Ciaramella · Sudbury, US
Shinu John · Cambridge, US
Andrew J. Bett · Lansdale, US
Danilo Casimiro · Harleysville, US
Dai Wang · Blue Bell, US
Lan Zhang · Forest Park, US

Key dates

Filing date	Mar 15, 2018
Grant date	Sep 12, 2023
Priority date	—
Expiry date	Mar 15, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.